Navigation Links
Sangamo BioSciences to Focus on Advancing ZFP Therapeutic Pipeline at J.P. Morgan Healthcare Conference
Date:1/8/2014

>Positive data from the Shire-partnered Huntington's disease program in animal models of the disease; and
  • Preclinical data and specific details of the ZFP Therapeutic approach to provide a potential cure for both sickle cell disease and beta-thalassemia. 
  • The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

    About Sangamo
    Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. As part of its acquisition of Ceregene Inc., Sangamo acquired a fully-enrolled and funded, double-blind, placebo-controlled Phase 2 trial to evaluate NGF-AAV (CERE-110) in Alzheimer's disease. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences an
    '/>"/>

    SOURCE Sangamo BioSciences, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
    2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
    3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
    4. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
    5. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
    6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
    7. Sangamo BioSciences Reports First Quarter 2013 Financial Results
    8. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
    9. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
    10. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
    11. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/24/2014)... novembre 2014  Surgical Theater LLC ha ... esposta durante l,apertura in data 24 novembre ... la Fondazione IRCCS Istituto Neurologico Nazionale "C. ... (strumento di pianificazione chirurgica) e Surgical Navigation ... avanzata) saranno presentati in occasione dell,evento dedicato ...
    (Date:11/24/2014)... , Nov. 24, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... Kim , President and CEO of Inovio Pharmaceuticals, will be ... to ring the Nasdaq Opening Bell tomorrow, Tuesday November 25, ... 15 th listing on the Nasdaq Global Select Market.  ... Kim said, "We are honored to ring the Nasdaq Opening ...
    (Date:11/23/2014)... 23, 2014  Aurobindo Pharma USA ... USP 300 mg 100-count bottles to the consumer level. ... empty capsules. Empty capsules could result in ... that could range from no effect, short term reduction ... (long period seizures) that could be life-threatening. Aurobindo Pharma ...
    Breaking Medicine Technology:La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 2La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 3La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 4Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 3Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2
    ... Academy of Ophthalmology Annual Meeting Describes ... Advance in Treatment of Endothelial Disease, NEW ... the American Academy of Ophthalmology,s Annual Meeting, Massimo Busin,MD, ... Serena,Hospital, Forli, Italy, described a technique that significantly improved,results ...
    ... NEW ORLEANS, La., Nov. 10 Ellex Medical ... design and manufacture of ophthalmic,laser and ultrasound systems, ... for non-thermal Retina Regeneration Therapy (Ellex,2RT(TM)). Results demonstrate ... and to reduce retinal edema in patients with,diabetic ...
    Cached Medicine Technology:Improved Cornea Surgery Technique Provides Enhanced Transplant Success 2Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 2Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 4
    (Date:11/24/2014)... 24, 2014 Mental health issues ... They break up families, ruin careers, and generally ... for those that suffer,” says Hardy Nutritionals® ... showing that our specialized nutritional treatments can reverse ... on “Mind Over Matter”, the premiere episode of ...
    (Date:11/24/2014)... California (PRWEB) November 24, 2014 Dr. ... Diego Fertility Center, recently appeared on NBC to discuss egg ... Egg freezing has been trending in the news recently, with ... expensive procedure for women. , “[The companies] see ... who are on a career hot path.” Says Dr. Kettel. ...
    (Date:11/23/2014)... The report, “Market Snapshot: Aesthetic Lasers ... Asia-Pacific” provides quantitative analysis of the three aesthetic ... body contouring devices, non-invasive body contouring devices and ... data by revenue and volume over the 2006 ... South Korea, Australia and India. It uses data ...
    (Date:11/23/2014)... holidays can be a challenge for families of children ... an expert says. "Holidays with family can be ... have children with special needs, some care must be ... of the Sciences in Philadelphia, said in a university ... or visitors know what special requirements are needed to ...
    (Date:11/23/2014)... NY (PRWEB) November 23, 2014 More ... past month in a federal litigation involving Byetta lawsuits ... diabetes medications, Bernstein Liebhard LLP reports. , A ... claims over a class of Type 2 diabetes medications ... in the U.S. District Court, Southern District of California, ...
    Breaking Medicine News(10 mins):Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4
    ... Inverness Medical Innovations, Inc. (NYSE: IMA ), a ... health at home through the merger of rapid diagnostics and ... of America and Merrill Lynch 2009 Health Care Conference being ... in New York City. Ron Zwanziger, Chief Executive Officer, ...
    ... Eclipsemed Ltd, a leading national distributor of ... Germany, a leading manufacturer of medical and aesthetic devices have ... featured on the Lifetime Network,s The Balancing Act ... and women,s issues. The program will air on Tuesday, May ...
    ... Make a Statement: Design for the Cure event representing Living ... hit reality television series "Project Runway," is participating in the ... the Cure event representing Living Positive By Design ... the event on Thursday, May 7th , Jack will ...
    ... in First Quarter ResultsHARRISBURG, Pa., May 7 ... its 2009 community outreach program has provided more ... underserved in the first quarter of 2009."The tough ... for the uninsured community to seek the proper ...
    ... and Makes Donation for Every Purchase of TENA(R) Women(TM) ... AlonePHILADELPHIA, May 7 This Mother,s Day, May 10, ... products and services under the globally-leading TENA ... up with Breast Cancer Network of Strength ...
    ... Announcing the upcoming publication of Neuromodulation , edited ... R. Rezai. , This book is the first comprehensive ... rapidly growing field of neuromodulation, by providing a complete ... applied to the brain, spinal cord, peripheral nerves, autonomic ...
    Cached Medicine News:Health News:Inverness Medical Innovations to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 12, 2009 2Health News:Body-Jet(R), State of the Art Water-Jet Assisted Liposuction Technology to be Featured on Lifetime Television Network, The Balancing Act 2Health News:'Project Runway' Designer in Chicago to Educate About Living with HIV and Combat Stigma Associated with the Disease 2Health News:'Project Runway' Designer in Chicago to Educate About Living with HIV and Combat Stigma Associated with the Disease 3Health News:'Project Runway' Designer in Chicago to Educate About Living with HIV and Combat Stigma Associated with the Disease 4Health News:United Concordia Provides $100,000 in Free Dental Services 2Health News:Breast Cancer Network of Strength(R) and SCA Personal Care North America, Through Its TENA(R) Brand, Team Up to Offer Support to Women Affected by Breast Cancer 2Health News:Breast Cancer Network of Strength(R) and SCA Personal Care North America, Through Its TENA(R) Brand, Team Up to Offer Support to Women Affected by Breast Cancer 3Health News:Breast Cancer Network of Strength(R) and SCA Personal Care North America, Through Its TENA(R) Brand, Team Up to Offer Support to Women Affected by Breast Cancer 4
    Unipolar Atrial "J" Lead...
    VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
    VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
    VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
    Medicine Products: